Free Newsletter
Transgenic monkeys made for research programs
Viral DNA was used to introduce a gene for a green fluorescent protein into monkeys, creating a new line of "glow-in-the-dark" transgenic primates for drug research work. Researchers involved in the instantly controversial project say this is the first time that a monkey has been genetically engineered so that a new gene entered into its DNA and was passed down to its offspring.
Scientists were able to create a transgenic monkey last year that could be used to study Huntington's disease, but the genetic rearrangement wasn't passed down to subsequent generations. Now scientists say this new approach will be able to develop a line of primates that can be genetically orchestrated to more closely match humans. That would give drug makers a better animal model for preclinical studies as they try to determine a drug's chances of working in people. In particular, the transgenic animals--which glow green under a fluorescent light--are expected to lead the way to new animal models that can be used for neurological diseases like Parkinson's and Huntington's disease.
The work by Japanese scientists was published in Nature and heralded by drug researchers. But animal rights groups and some bioethicists were quick to condemn the genetic engineering work.
"We may find ourselves gradually drifting towards the genetic engineering of human beings," said Dr David King, from the group Human Genetics Alert.
- read the report from the Washington Post
- read the story from Sky News with some of the reaction
Related Articles:
Transgenic tobacco used to create diabetes drug
BIO heralds rules on genetically designed animals
FDA approves GTC's transgenic drug ATryn
Regulators focusing on transgenic animals
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: